APA (7th ed.) Citation

Lingor, P., Weber, M., Camu, W., Friede, T., Hilgers, R., Leha, A., . . . Zielke, E. (2019). ROCK-ALS: Protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the Rho kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis. Frontiers in neurology, 10, . https://doi.org/10.3389/fneur.2019.00293

Chicago Style (17th ed.) Citation

Lingor, Paul, et al. "ROCK-ALS: Protocol for a Randomized, Placebo-controlled, Double-blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis." Frontiers in Neurology 10 (2019). https://doi.org/10.3389/fneur.2019.00293.

MLA (9th ed.) Citation

Lingor, Paul, et al. "ROCK-ALS: Protocol for a Randomized, Placebo-controlled, Double-blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis." Frontiers in Neurology, vol. 10, 2019, https://doi.org/10.3389/fneur.2019.00293.